resolutionmini

mise à jour du
11 novembre 2002
Life Sciences
1991; 48; PL-129
lexique
Is dopamine-agonist induced yawning beravior a D3 mediated event?
Richard M. Kostrzewa and Ryszard Brus
Department of Pharmacology James H. Quillen College of Medicine East Tennessee State University Johnson City, TN 37614 and
Department of Pharmacology Silesian Academy of Medicine 41-808 Zabrze, Poland

Chat-logomini

Low doses of dopamine agonists produce yawning behavior in male rats with a bell-shaped dose-effect curve. At least part of the explanation for this response curve is that higher doses of agonists induce competing behaviors, including the stereotyped actions that are commonly associated with this class of agents (1, 2). Up until recently it was felt that quinpirole was a selective dopamine D2 receptor agonist (3). However, with the discovery of a dopamine D3 receptor, it is now realized that quinpirole has a 100-fold greater affinity for D3 vs. D2 receptors (4). Because of the fact that extremely low doses of dopamine receptor agonists, including quinpirole, induce yawning behavior in the absence of other effects, it seems that yawning behavior may represent a D3-mediated process. If so, this would be one means of assessing functional changes in D3 receptors, including induction of supersensitivity by various conditions and after different drug treatments. Should this hypothesized association between D3 receptor activation and yawning response be valid, then there is evidence that yawning behavior, and presumably D3 receptors, can be supersensitized by daily quinpirole treatment during postnatal ontogeny (5). This animal model may be useful for studying biochemical mechanisms of D3 receptor supersensitivity. Of the various candidate behaviors for assessing D3 receptors, quinpirole-induced yawning is one deserving attention.

References

  1. A.J.GOWER, H.H.G.BERENDSEN, M.M.PRINCEN, C.L.E.BROEKKAMP, Eur. J.Pharmacol. 103 81-89 (1984).
  2. R.LONGONI, T.SPINA, G.DI CHIARA, Eur. J. Pharmacol. 134 163-173 (1987).
  3. K.TSURUTA, E.A.FREY, C.W.GREWE, T.E.COTE, R.L.ESKAY, J.W.KEBABIAN, Nature (Lond) 292 463-465 (1981).
  4. P.SOKOLOFF, B.GIROS, M.-P.MARTRES, M.-L.BOUTHENET, J.-C.SCHWARTZ, Nature (Lond) 347 146-151 (1990).
  5. R.M.KOSTRZEWA, R.BRUS, Pharmacol. Biochem. Behav. (1991)
 
 
Mogilnicka E, Klimek V Drugs affecting dopamine neurons and yawning behavior. Pharmacol Biochem Behav 1977; 7; 303-305
R Brus , R Szkilnik, RM Kostrzewa Nitric oxide (NO) and central dopamine (DA) D3 receptor reactivity to quinpirole in rats Act Neurobiol Exp 1996; 56; 15-19
Kostrzewa RM and R Brus Is dopamine-agonist induced yawning behavior a D3 mediated event? Life Sci 1991; 48; 26; 129
Kostrzewa RM, Brus R. Ontogenic homologous supersensitization of quinpirole-induced yawning in rats. Pharmacol Biochem Behav. 1991;39(2):517-519.
Kostrzewa RM, Brus R, Rykaczewska M, Plech A. Low-dose quinpirole ontogenically sensitizes to quinpirole-induced yawning in rats. Pharmacol Biochem Behav. 1993;44(2):487-489.
Eguibar JR et al Behavioral differences between selectively bred rats: D1 versus D2 receptors in yawning and grooming Pharmacology; Biochemistry and Behavior 2003; 74; 827-832
Spina, R Longoni, A Mulas, G di Chiara SKF 38393 potentiates yawning induced by LY 171555: further evidence against the autoreceptor hypothesis of yawning Psychopharmacology 1989; 98; 567-568
Oswiecimska J, Brus R, Szkilnik R, Nowak P, Kostrzewa RM 7-OH-DPAT, unlike quinpirole, does not prime a yawning response in rats Pharmacol Biochem Behav. 2000; 67; 11-15
Nowak P, Labus L, Kostrzewa RM, Brus R. DSP-4 prevents dopamine receptor priming by quinpirole Pharmacol Biochem Behav. 2006;84(1):3-7
 
 -Fugikawa M; Yamada K; Nagashima M; Furukawa T Involvement of beta-adrenoreceptors in regulation of the yawning induced by neuropeptides; oxytocin and alpha-melanocytes stimuling hormone in rats. Pharmacol Biochem Behav 1995; 50; 339-343
-Furukawa T Yawning behavior for preclinical drug evaluation Meth Find Exp Clin Phamacol 1996; 18; 2; 141-155
-Kimura H; Yamada K; Nagashima M; Matsumoto S Role of adrenergic neuronal activity in the yawning induced by tacrine and NIK-247 in rats.Pharmacol Biochem Behav 1992; 43; 4; 985-91
-Kimura H; Yamada K; Nagashima M; Furukawa T Involvement of catecholamine receptor activities in modulating the incidence of yawning in rats.Pharmacol Biochem Behav 1996; 53(; 4; 1017-21
Ogura H, Kosasa T, Kuriya Y, Yamanishi Y Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. Eur J Pharmacol. 2001; 415; 2-3; 157-64
-Matsumoto S, Yamada K, Nagashima M, Matsuo N, Shirakawa K, Furukawa T Potentiation by serotonergic inhibition of yawning induced by dopamine receptor agonists in rats.Pharmacol Biochem Behav 1989; 32; 3; 815-8
-Serra G , Collu M and Gessa GL Yawning is elicited by D2 dopamine agonists but is blocked by D1 antagonist Psychopharmacology 1987; 91; 330-337
-Serra G, Gessa GL Hypophysectomy prevents yawning and penile erection but not hypomotility induced by apomorphine Pharmacology Biochemistry & Behavior 1983; 19; 917-919
-Serra G et al Cycloheximide prevents apomporphine induced yawning, penile erection and genital grooming in rats European Journal of Pharmacology1983; 86; 279-282
-Kostrzewa RM and R Brus Is dopamine-agonist induced yawning behavior a D3 mediated event? Life Sci 1991; 48; 26; 129
-Ushijima I, Mizuki Y, Yamada M Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning Psychopharmacology (Berl) 1988; 95; 34-7
-Ushijima I et al, Muscarinic and nicotinic effects on yawning and tongue protruding in the rat Pharmacol Biochem Behavior 1984; 21; 297-300
-Ushijima et al modification of apomorphine, physiostigmine and pilocarpine induced yawning after long term treatment with neuroleptic or cholinergic agents Arch Int Pharmacodyn 1984; 271; 180-188
-Ushijima I et al Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine Arch Int Pharmacodyn 1985; 273; 196-201
-Ushijima, I., Y. Mizuki, et al. Behavioral effects of dilazep on cholinergic, dopaminergic, and purinergic systems in the rat. Pharmacol Biochem Behav 1992;43(3): 673-676.
-Yamada K, Furukawa T Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning Psychopharmacology 1980; 67; 39-43
-Yamada K, Furukawa T The yawning elicited by alpha-melanocyte-stimulating hormone involves serotonergic -dopaminergic - cholinergic neuron link in rats Naunyn-Schmiedeberg's Arch Pharmacol 1981; 316; 155 -160
-Yamada K et al Involvement of septal and striatal dopamine D2 receptors in yawning behavior in rats Psychopharmacology 1986; 90; 9-13
-Yamada K et al Possible involvement of differing classes of dopamine d2 receptors in yawning and stereotypy in rats Psychopharmacology 1990; 100; 141-144
-Yamada K, Furukawa T Behavioral studies on central dopaminergic neurons. especially jumping, stretching, body shaking and yawning behavior J PharmacoBio dynamics 1980; 3; S16-S18
-Yamada K, Matsumoto S, Nagashima M, Kumagai M, Matsuo N, Furukawa T Stimulatory effects of beta-adrenoceptor blockers on the yawning induced by dopaminergic and cholinergic agonists in rats. Japanese J Pharmacology 1987; 43; supp53p
-Yamada K, S Matsumoto, M Nagashima, K Shirakawa, T Furukawa Potentiation of yawning responses to the dopamine receptor agonists B-HT 920 and SND 919 by pindolol in the rat J Neural Transm [GenSect] 1990; 79; 19-24